JOJunwen Ou

Junwen Ou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Junwen Ou has a total of 103 co-authors. Here are the top co-authors by number of shared publications:

  • Yanping Du

    Clifford Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China

    4 shared publications
  • Clifford L.K. Pang

    Cancer Center, Clifford Hospital, Jinan University, Guangzhou, PR China

    3 shared publications
  • Kexin Li

    Imaging Department, Clifford Hospital, Jinan University, Guangzhou, PR China

    2 shared publications
  • Qichun Cai

    Cancer Center, Clifford Hospital, Jinan University, Guangzhou, PR China

    2 shared publications
  • Qiong Meng

    Cancer Center, Clifford Hospital, Jinan University, Guangzhou, PR China

    2 shared publications
  • Qiulin Liao

    Pathology Department, Clifford Hospital, Jinan University, Guangzhou, PR China

    2 shared publications

Latest Publications

  • Open Access

    An integrated transcriptomic analysis unveils the regulatory roles of RNA binding proteins during human spermatogenesis

    by Ning Xu, Yixian Qin, Yu Liu, Yudong Guan, Hang Xin, Junwen Ou, Yiqiao Wang

    Background: RNA-binding proteins (RBPs) have emerged as key regulators in testis development and spermatogenesis, yet a comprehensive understanding of their expression dynamics has been lacking.Methods: This study leverages published single-cell RNA sequencing (scRNA-seq) data to elucidate the complex expression patterns of RBP genes during postnatal testis development and spermatogenesis. Additionally, it uses bulk RNA-seq data to explore the regulatory impact of RBPs on alternative splicing (AS) in non-obstructive azoospermia (NOA).Results: We have identified cell-specific RNA-binding protein (RBP) genes in various cell types throughout testis development. Notably, distinct RBP gene clusters exhibit significant differential expression, particularly in Sertoli cells as they mature from neonatal to adult stages. Our analysis has revealed temporally-regulated RBP clusters that correlate with the developmental progression of Sertoli cells and the advancement of spermatogenesis. Moreover, we have established links between specific RBPs and the pathogenesis of non-obstructive azoospermia (NOA) through the regulation of alternative splicing (AS) events. Additionally, RPL10, RPL39, and SETX have been identified as potential diagnostic biomarkers for NOA.Conclusion: This research provided an in-depth look at RBP expression patterns during human testis development and spermatogenesis. It not only deepens our basic comprehension of male fertility and infertility but also indicates promising directions for the creation of innovative diagnostic and treatment methods for NOA.


  • Open Access

    Shengxue Busui Decoction activates the PI3K/Akt and VEGF pathways, enhancing vascular function and inhibiting osteocyte apoptosis to combat steroid-induced femoral head necrosis

    by Manting Liu, Jiexiang Ye, Runtian Wu, Dongqiang Luo, Tao Huang, Dandan Dai, Kexin Wang, Yanping Du, Junwen Ou

    Introduction: Steroid-induced osteonecrosis of the femoral head (SONFH) is a debilitating condition with no specific treatment. Inhibiting osteocyte apoptosis may be a promising therapeutic approach. Shengxue Busui Decoction (SBD) has shown protective effects against SONFH, but its mechanisms are not fully understood. This study aims to investigate the effects of SBD on SONFH in rats, identifying its key active components and regulatory mechanisms using network pharmacology, bioinformatics, machine learning, and experimental validation.Methods: Key active components and disease targets of SBD were identified through network pharmacology and bioinformatics. GO/KEGG enrichment and ssGSEA analyses were performed to identify critical pathways. Cytoscape and machine learning (SVM) were used for target prediction and molecular docking validation. A dexamethasone (Dex)-induced SONFH rat model was established, and SBD was administered for 60 days. Histological changes were assessed via HE staining, osteoclast activity through TRAP staining, apoptosis levels with TUNEL assays, and vascular function through hematological tests. ELISA was used to measure ALP and OCN levels. In vitro, Dex-induced osteoblast apoptosis in MC3T3-E1 cells was examined to assess SBD’s effect on osteoblast proliferation, apoptosis, and signaling. Western blotting analyzed Caspase-9, Caspase-3, Bax, Bcl-2, and pathway-related proteins. ALP and Alizarin Red staining evaluated osteoblast differentiation and mineralization.Results: Network pharmacology identified curcumin, berberine, and diosgenin as key active components of SBD, with the PI3K/Akt and VEGFR pathways as critical targets, and RAF1, FOXO3, and BRAF as hub genes. In vivo, SBD intervention significantly reduced bone structural damage and apoptosis, decreasing the rate of empty bone lacunae. SBD also increased osteogenic markers ALP and OCN in SONFH rats. In vitro, SBD inhibited osteoblast apoptosis, promoted PI3K/Akt and VEGF pathway expression, and enhanced osteoblast differentiation and mineralization.Conclusion: This study integrates network pharmacology with experimental validation, showing that SBD protects against SONFH by inhibiting osteoblast apoptosis via PI3K/Akt and VEGFR pathways. SBD promotes osteoblast differentiation and mineralization, improving bone structure and vascular function. Curcumin, berberine, and diosgenin are likely key contributors to these effects, highlighting SBD as a potential therapeutic strategy for SONFH.


  • SERPINE1 and SERPINB7 as potential biomarkers for intravenous vitamin C treatment in non-small-cell lung cancer

    by Junwen Ou, Qiulin Liao, Yanping Du, Wentao Xi, Qiong Meng, Kexin Li, Qichun Cai, Clifford L.K. Pang


  • Open Access

    SERPINB7, TMEM158, and SERPINE1 signature as predictors of non-small-cell lung cancer prognosis after intravenous vitamin C treatment

    by Junwen Ou, Qiulin Liao, Yanping Du, Wentao Xi, Qiong Meng, Kexin Li, Qichun Cai, Clifford L.K. Pang

    Background: Vitamin C (VitC) has been proposed as a potential anti-cancer agent for prolonging progression-free survival (PFS) and overall survival (OS) in non-small-cell lung cancer (NSCLC) patients. However, VitC has only been shown to be effective for some patients, and the mechanism in those who have benefitted from it remains unknown. We aimed to explore whether gene expression could predict IVC benefit for patients with NSCLC. Methods: H1299 and PC9 cells were treated with VitC and high-throughput sequencing was used for screening differential genes. Data from the Kaplan-Meier Plotter and the Human Protein Atlas databases were used for analysis of patient prognoses. In a retrospective study, 153 NSCLC patients from our Cancer Center were selected and divided into a control group (n = 81) and VitC group (n = 72) for immunohistochemical staining and prognosis analysis. Results: As a result, ZNF507, DLX4, and DDIT4 were found to be upregulated, and SERPINB7, TMEM158 and SERPINE1 downregulated in NSCLC cell lines following VitC treatment. Combined patient data from the cohort analysis and online databases revealed that the downregulated genes, but not upregulated genes, presented an unfavorable prognostic predictor of OS in NSCLC patients. Further analysis showed that the combined three genes were more efficient at predicting survival than individually (AUC=0.77, 95%CI, 0.63-0.90). Moreover, high expression of SERPINB7, TMEM158, and SERPINE1 in resected tumour- tissues before VitC treatment was found to be associated with prolonged OS in patients with NSCLC who were treated with VitC. Conclusion: Overall, these data revealed that SERPINB7, TMEM158, and SERPINE1 formed a novel NSCLC prognosis gene set and could serve as a potential therapeutic target as well as predictive factor for VitC treatment in patients with NSCLC. Trial registration: Retrospectively registered (No: 2/2021-PRE-48) on July 13, 2021.

  • Open Access

    Nutritional status and survival of 8247 cancer patients with or without diabetes mellitus—results from a prospective cohort study

    by Minghua Cong, Wenjie Zhu, Chang Wang, Zhenming Fu, Chunhua Song, Zhong Dai, Keqing Yao, Zengqing Guo, Yuan Lin, Yingying Shi, et al.

    Background: The number of cancer patients with diabetes mellitus (DM) is steadily rising. Little is known about the nutritional status of this population. This study characterized the nutritional status and survival of cancer patients with diabetes compared with those without diabetes.Methods: A total of 8247 cancer patients were prospectively enrolled from 72 hospitals in China and followed until August 2019. A global estimation of the nutritional status was performed for each participant using standardized tools. The outcomes were cancer‐specific survival (CSS) and overall survival (OS).Results: The incidence of diabetes was 7.6% in the whole population. In comparison with the non‐DM group, the DM group had greater body weight, but a similar fat‐free mass, a lower handgrip strength and a decreased Karnofsky performance score. A higher proportion of patients with diabetes were overweight/obese as indicated by BMI. The percentage of patients who were at risk of malnutrition (evaluated by PG‐SGA) was higher in the DM group (score ≥ 4, 56.7% vs 52.9%). Patients with DM showed a worse CSS (4‐year CSS, 62% vs 73%) and OS (4‐year OS 39% vs 52%). Diabetes was associated with an increased risk of both cancer‐specific (hazard ratio (HR) = 1.282, 95% confidence interval (CI) 1.070‐1.536) and overall (HR = 1.206, 95% CI 1.040‐1.399) mortality.Conclusions: Cancer patients with diabetes had a larger body mass but lower muscle strength, poorer performance status and higher incidence of malnourishment. Diabetes was associated with compromised survival. Tailored nutritional intervention is necessary for this subpopulation of patients.


  • Open Access

    A randomized phase II trial of best supportive care with or without hyperthermia and vitamin C for heavily pretreated, advanced, refractory non-small-cell lung cancer

    by Junwen Ou, Xinyu Zhu, Pengfei Chen, Yanping Du, Yimin Lu, Xiufan Peng, Shuang Bao, Junhua Wang, Xinting Zhang, Tao Zhang, et al.


  • Open Access

    A Retrospective Study of Gemcitabine and Carboplatin With or Without Intravenous Vitamin C on Patients With Advanced Triple-Negative Breast Cancer

    by Junwen Ou, Xinyu Zhu, Hongyu Zhang, Yanping Du, Pengfei Chen, Junhua Wang, Xiufan Peng, Shuang Bao, Xinting Zhang, Tao Zhang, et al.

    Background: This is a retrospective study to examine the effect of chemotherapy with or without intravenous vitamin C (IVC) on women with advanced triple-negative breast cancer (TNBC). Methods: From 2008 to 2016, a total of 113 patients with pathologically confirmed TNBC at Clifford Hospital were evaluated, and 70 patients were matched and divided into IVC (treatment group) and non-IVC groups (control group). The match was according to age, menopausal status, and metastatic sites. In the control group, 35 patients received gemcitabine and carboplatin. In the treatment group, 35 patients received the same chemotherapy plus IVC. Results: Baseline characteristics were not significantly different between the 2 groups. According to the criteria of RECIST 1.1 (Response Evaluation Criteria in Solid Tumors), enhanced computed tomography scan was compared after 2 cycles of chemotherapy. In the treatment group, 2/35 cases had a complete remission (CR), 15/35 cases had partial remission (PR), and 13/35 cases had stable disease (SD). The response rate was 48.6%. In the control group, there were no CR cases, 14/35 cases had PR, 14/35 cases had SD, and the response rate was 40.0% (P > .05). The median progression-free survival time and median overall survival time was 7 months (95% confidence interval [CI] =1.5-28.5 months) and 27 months (95% CI = 4-40 months) in the treatment group compared with 4.5 months (95% CI = 1.5-8 months) and 18 months (95% CI = 3-26 months) in the control group (P < .05). All patients experienced diverse reactions in the gastrointestinal tract and myelosuppression. The incidence of adverse reactions in the treatment group was significantly lower than that of the control group (P < .05). Conclusion: IVC may have an effect on improving the prognosis of patients with advanced TNBC.